Biohaven (BHVN) announced the completion of enrollment in a Phase 2 proof-of-concept study with its myostatin-activin pathway inhibitor, taldefgrobep alfa, which offers the potential to achieve high-quality weight loss in people living with obesity. Topline data from the study are expected in 2H 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven price target raised to $30 from $15 at TD Cowen
- Biohaven price target raised to $27 from $24 at Goldman Sachs
- Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate
- Biohaven fractionally lower after Xenon reports azetukalner Phase 3 hit target
- Controversial Prasad leaving FDA, NYT reports